

II . Financial highlights (more detail will be available in Page 4 and onward)

Sales and earnings (Billions of Yen)	FY08	FY09	FY10	FY11	Estimate FY2012	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease
Net Sales	1,538.3	1,466.0	1,419.4	1,508.9	1,550.0	702.5	786.9	84.4	12.0%
Operating Income	306.5	420.2	367.1	265.0	160.0	211.0	108.6	-102.5	-48.6%
<% of net sales>	<19.9%>	<28.7%>	<25.9%>	<17.6%>	<10.3%>	<30.0%>	<13.8%>	<-16.2pt>	
Ordinary Income	327.2	415.8	371.6	270.3	150.0	209.6	113.1	-96.5	-46.0%
<% of net sales>	<21.3%>	<28.4%>	<26.2%>	<17.9%>	<9.7%>	<29.8%>	<14.4%>	<-15.5pt>	
Net Income	234.4	297.7	247.9	124.2	155.0	135.7	119.8	-15.9	-11.7%
<% of net sales>	<15.2%>	<20.3%>	<17.5%>	<8.2%>	<10.0%>	<19.3%>	<15.2%>	<-4.1pt>	
EBITDA	446.9	532.1	484.1	422.6	345.0	266.7	213.4	-53.3	-20.0%
<% of net sales>	<29.1%>	<36.3%>	<34.1%>	<28.0%>	<22.3%>	<38.1%>	<27.1%>	<-11.0pt>	
R&D Expenses	453.0	296.4	288.9	281.9	310.0	119.0	154.7	35.7	30.0%
<% of net sales>	<29.5%>	<20.2%>	<20.4%>	<18.7%>	<20.0%>	<16.9%>	<19.7%>	<2.7pt>	
Overseas Sales	843.1	777.0	698.1	775.5	790.0	335.5	418.7	83.2	24.8%
<% of net sales>	<54.8%>	<53.0%>	<49.2%>	<51.4%>	<51.0%>	<47.8%>	<53.2%>	<5.4pt>	
Net Sales of Ethical drugs segment	1,384.1	1,317.7	1,267.4	1,358.8	1,400.0	627.0	710.4	83.4	13.3%

Business segment * (Billions of Yen)	FY08	FY09	FY10	FY11	FY2011 1-2Q Total	FY2012 1-2Q Total	vs. FY2011 1-2Q Total	increase/ decrease
Net Sales	1,538.3	1,466.0	1,419.4	1,508.9	702.5	786.9	84.4	12.0%
Pharmaceuticals	1,448.5							
Ethical drugs	1,384.1	1,317.7	1,267.4	1,358.8	627.0	710.4	83.4	13.3%
Japan	549.0	548.9	578.5	592.2	296.0	296.3	0.2	0.1%
Overseas	835.1	768.9	689.0	766.6	331.0	414.1	83.1	25.1%
Consumer Healthcare	64.4	58.2	60.3	61.7	31.8	33.6	1.8	5.6%
Others	89.9							
Others		94.8	96.3	93.1	46.0	45.2	-0.8	-1.6%
Adjustments		-4.8	-4.6	-4.6	-2.3	-2.3	0.1	
Operating Income	306.5	420.2	367.1	265.0	211.0	108.6	-102.5	-48.6%
Pharmaceuticals	296.9							
Ethical drugs		400.6	346.0	243.8	198.4	95.3	-103.0	-51.9%
Consumer Healthcare		11.0	12.2	11.8	7.5	8.4	1.0	13.4%
Others	9.5							
Others		10.8	11.0	11.7	6.3	5.8	-0.5	-8.3%
Adjustments		-2.2	-2.2	-2.2	-1.1	-1.0	0.1	

* Effective from the FY2010, the Accounting Standard for Disclosures about Segments of an Enterprise and Related Information has been adopted. The figures for "FY09" are calculated and indicated after applying said accounting standard.

ROE•EPS•Dividend (Yen)	FY08	FY09	FY10	FY11	Estimate FY2012	FY2011 1-2Q Total	FY2012 1-2Q Total
ROE (Return on equity)	10.9%	14.4%	11.8%	6.1%	7.7%	13.3%	12.2%
EPS (Earnings per share)	289.82	377.19	314.01	157.29	196.35	171.85	151.74
Pro Forma EPS (Earnings per share) *	470.30	448.81	373.57	314.38	240.68	199.68	149.79
Annual dividends per share	180.00	180.00	180.00	180.00	180.00	90.00	90.00
Payout ratio	62.1%	47.7%	57.3%	114.4%	91.7%	52.4%	59.3%

* Excluding extraordinary gains and losses and special factors related to corporate acquisitions and others.

Balance sheets (Billions of Yen)	FY08	FY09	FY10	FY11	FY2011 2Q End	FY2012 2Q End	vs. FY11
Current assets	1,475.6	1,572.9	1,586.3	1,279.0	1,274.5	1,241.8	-37.2
Tangible fixed assets	258.5	318.9	407.5	488.7	474.5	489.6	0.9
Intangible fixed assets	747.7	639.9	517.4	1,516.2	1,461.5	1,476.2	-40.0
Investment and other assets	278.4	291.6	275.2	293.1	288.8	274.6	-18.5
Total assets	2,760.2	2,823.3	2,786.4	3,577.0	3,499.3	3,482.2	-94.9
Current liabilities	472.1	428.5	436.6	751.7	1,017.2	488.3	-263.5
Long-term liabilities	234.2	230.1	213.2	753.4	437.0	1,022.7	269.3
Total liabilities	706.3	658.5	649.7	1,505.2	1,454.2	1,511.0	5.8
Net assets	2,053.8	2,164.7	2,136.7	2,071.9	2,045.1	1,971.2	-100.7
Shareholders' equity	2,124.4	2,278.5	2,384.2	2,366.4	2,448.9	2,406.8	40.3
Accumulated other comprehensive income ^(*)	-113.0	-157.3	-292.6	-354.6	-461.6	-494.7	-140.1
Stock acquisition right	0.1	0.2	0.3	0.5	0.4	0.7	0.1
Minority interests	42.4	43.4	44.7	59.5	57.3	58.5	-1.1

(*) The amounts of "Valuation and translation adjustments" in the previous years are shown as "Accumulated other comprehensive income" from the fiscal year end 2010.

Shareholder's Equity Ratio (%)	72.9%	75.1%	75.1%	56.2%	56.8%	54.9%	-1.3pt
Treasury Stock (Billions of Yen)	1.1	1.0	1.0	0.8	0.9	0.6	-0.2

Shares	FY08	FY09	FY10	FY11	FY2011 2Q End	FY2012 2Q End
Number of shares outstanding (1,000)	789,666	789,666	789,666	789,666	789,666	789,666
(Treasury Stock (1,000))	(303)	(286)	(295)	(252)	(266)	(215)
Stock price at year-end (Yen)	3,400	4,115	3,880	3,645	3,680	3,595
Total market value (Billions of Yen)	2,684.9	3,249.5	3,063.9	2,878.3	2,906.0	2,838.8

Number of employees (**)	FY08	FY09	FY10	FY11	FY2011 2Q End	FY2012 2Q End	vs. FY11
Consolidated	19,362	19,585	18,498	30,305	30,804	30,814	509
(Unconsolidated)	(6,124)	(6,334)	(6,471)	(6,565)	(6,620)	(6,655)	(90)

(**) Employees working in Takeda Pharmaceutical Company Limited and its consolidated subsidiaries. From "FY10", the numbers are indicated on the full time equivalent basis. For fair comparison, the numbers of "FY09" are modified according to the new basis.

Exchange rate(Yen)	FY08	FY09	FY10	FY11	FY2011 1-2Q	FY2012 1-2Q	Estimate FY2012 3-4Q
US\$ Average (Apr.-Mar.)	101	93	86	79	80	80	80
Euro Average (Apr.-Mar.)	143	131	113	109	114	101	99